Akebia Therapeutics Inc FY2024 Q3 Financial Analysis: Net Income Decreased 38.4%

Executive Summary

In the third quarter of fiscal year 2024, Akebia Therapeutics reported a net loss of $20.04 million, representing a 38.4% decrease compared to the net loss of $32.55 million in the same period last year. Revenue declined by 11.0%, from $42.05 million to $37.43 million. The company’s cash position decreased slightly to $35.69 million, while total liabilities increased significantly, primarily driven by long-term debt and non-current liabilities. Operating cash flow remained negative at approximately $6.7 million, reflecting ongoing investments and operational challenges. Despite revenue pressures, the company maintains a solid cash reserve and manageable debt levels, positioning for strategic growth and operational improvements.

Management Discussion and Analysis (MD&A)

Akebia’s Q3 FY2024 results highlight a challenging period characterized by declining revenues and increased operating expenses. The revenue decrease of 11.0% is primarily attributable to lower product sales and delayed commercialization efforts. Gross profit declined slightly to $23.27 million, with gross margin remaining stable at approximately 62.2%. Operating expenses, including research and development, remain high at $8.49 million, reflecting ongoing R&D investments. The net interest expense persisted at around $6.66 million, consistent with previous periods. The company’s net loss widened compared to prior year, emphasizing the need for strategic adjustments to improve profitability. Cash flow from operations remains negative, underscoring the importance of optimizing working capital and cost management.

Income Statement Analysis

Revenue for Q3 FY2024 was $37.43 million, down 11.0% from $42.05 million in Q3 FY2023. Gross profit stood at $23.27 million, with a gross margin of 62.2%, slightly lower than 57.1% in the prior year. Operating expenses, including R&D and SG&A, totaled $35.77 million, leading to an operating loss of $12.51 million, compared to a loss of $13.09 million in the previous year. Net income from continuing operations was a loss of $20.04 million, a decrease of 38.4% from the prior year’s loss of $31.49 million. Earnings per share (EPS) was -$0.0953, reflecting ongoing investment and operational costs. The YoY decline in net income underscores the need for revenue growth and cost control.

Balance Sheet Analysis

As of September 30, 2024, Akebia’s total assets were valued at $207.14 million, a decrease from $234.99 million in the prior year. Cash and cash equivalents declined to $35.69 million from $46.53 million. Accounts receivable increased slightly to $32.17 million. Inventory rose to $20.49 million, indicating inventory build-up or supply chain adjustments. Total liabilities increased significantly to $257.54 million, driven by long-term debt of $38.36 million and other non-current liabilities totaling $148.54 million. Total stockholders’ equity was negative at -$50.40 million, reflecting accumulated losses and retained earnings of -$1.66 billion. Liquidity remains manageable with a net debt position of approximately $14.56 million, but leverage levels warrant monitoring.

Cash Flow Analysis

Operating cash flow was negative at approximately $6.70 million, primarily due to net income loss and working capital changes. Investing activities involved minimal capital expenditures of $29,000, with no significant acquisitions or asset sales. Financing activities generated net cash inflow of about $1.22 million, mainly from net stock issuance of $1.75 million and minor debt repayment. The net change in cash was a decrease of $5.48 million, ending the period with cash of $35.69 million. The company continues to invest in R&D and operational infrastructure, which impacts short-term cash flow but supports long-term growth prospects.

Ratios & DuPont Analysis

Key financial ratios for Q3 FY2024 include a net profit margin of -53.6%, reflecting ongoing losses. Return on assets (ROA) is approximately -9.7%, and return on equity (ROE) is about -39.8%, indicating significant profitability challenges. Asset turnover remains low at 0.18, and the equity multiplier is 4.11, suggesting high leverage. These ratios highlight the company’s need to improve operational efficiency and profitability while managing leverage prudently.

Risk Factors

Major risks include regulatory uncertainties affecting drug approvals, market competition from established and emerging therapies, operational risks related to supply chain and manufacturing, financial risks from high debt levels, and macroeconomic factors such as healthcare policy changes and economic downturns. The company’s ability to achieve revenue growth and control costs will be critical to mitigating these risks.

Notes & Additional Commentary

Q3 FY2024 results reflect continued investment in R&D and commercialization efforts, which have yet to translate into positive profitability. The increase in liabilities and negative equity position indicate ongoing financial challenges. Unusual items include significant non-cash expenses such as depreciation and stock-based compensation. No extraordinary gains or losses were reported during this period.

Investment Implications

While Akebia faces near-term profitability challenges, its strong cash reserves and manageable debt levels provide a buffer for strategic investments. The company’s focus on pipeline development and potential market expansion could offer long-term growth opportunities. Investors should weigh the risks of continued losses against the potential for future revenue generation, considering the company’s R&D pipeline and market positioning. A balanced approach with close monitoring of operational improvements and financial health is recommended.